Diabetic Retinopathy - Pipeline Review, H2 2016

 

Rating

4.8 Star Rating for report Diabetic Retinopathy - Pipeline Review, H2 2016
4.8 / 5 stars rating
Pages: 237
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2016, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic retinopathy is a complication of diabetes that affects the eyes. Diabetic retinopathy symptoms may include spots or dark strings floating in your vision (floaters), blurred vision, fluctuating vision, vision loss and difficulty with color perception. The predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8826IDBPituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Revie...Dec 2016
Report... 05IB-GMDHC8814IDBHyperglycemia - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8807IDBFamilial Amyloid Neuropathies - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8762IDBHeterozygous familial hypercholesterolemia (heFH) - Pipeline Rev...Nov 2016
Report... 05IB-GMDHC8737IDBHomozygous Familial Hypercholesterolemia (HoFH) - Pipeline Revie...Nov 2016
Report... 05IB-GMDHC8697IDBHypercholesterolemia - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8696IDBDiabetic Foot Ulcers - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8653IDBDiabetic Neuropathy - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8770IDBType 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016Nov 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-11-16 

Report: Diabetic Retinopathy - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Diabetic Retinopathy Overview 10
Therapeutics Development 11
Pipeline Products for Diabetic Retinopathy - Overview 11
Pipeline Products for Diabetic Retinopathy - Comparative Analysis 12
Diabetic Retinopathy - Therapeutics under Development by Companies 13
Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes 17
Diabetic Retinopathy - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Diabetic Retinopathy - Products under Development by Companies 22
Diabetic Retinopathy - Products under Investigation by Universities/Institutes 26
Diabetic Retinopathy - Companies Involved in Therapeutics Development 27
Acucela Inc. 27
Aerie Pharmaceuticals, Inc. 28
Aerpio Therapeutics, Inc. 29
Amakem NV 30
Antisense Therapeutics Limited 31
Araim Pharmaceuticals, Inc. 32
BCN Peptides, S.A. 33
Biomar Microbial Technologies 34
Charlesson LLC. 35
Coherus BioSciences, Inc. 36
Crinetics Pharmaceuticals, Inc. 37
Diffusion Pharmaceuticals Inc 38
Dimerix Bioscience Pty Ltd 39
Dynamis Therapeutics, Inc. 40
EyeGene Inc 41
Foresee Pharmaceuticals, LLC 42
Formycon AG 43
Icon Bioscience, Inc. 44
Islet Sciences, Inc. 45
Kodiak Sciences Inc. 46
Kowa Company, Ltd. 47
LegoChem Biosciences, Inc 48
Lpath, Inc. 49
M's Science Corporation 50
Mabion SA 51
MingSight Pharmaceuticals 52
OcuCure Therapeutics, Inc. 53
Oculis ehf 54
Ohr Pharmaceutical Inc. 55
PanOptica, Inc. 56
Profarma 57
Promedior, Inc. 58
Regeneron Pharmaceuticals Inc 59
Retrotope, Inc 60
Ribomic Inc. 61
Stelic Institute & Co., Inc. 62
Stemedica Cell Technologies, Inc. 63
Strongbridge Biopharma plc 64
Sucampo Pharmaceuticals, Inc. 65
Targazyme, Inc. 66
ThromboGenics NV 67
TWi Pharmaceuticals, Inc. 68
VESSL Therapeutics Ltd 69
Diabetic Retinopathy - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 76
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 84
(irbesartan + propagermanium) - Drug Profile 84
A-717 - Drug Profile 87
AC-301 - Drug Profile 88
aflibercept - Drug Profile 89
AKB-9778 - Drug Profile 100
ALG-1001 - Drug Profile 104
AMA-0428 - Drug Profile 107
APTA-1004 - Drug Profile 108
Aptamers for Diabetic Retinopathy - Drug Profile 109
AR-13154 - Drug Profile 110
atesidorsen sodium - Drug Profile 111
Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 119
BNN-27 - Drug Profile 120
cibinetide - Drug Profile 121
CLT-005 - Drug Profile 124
CLT-020 - Drug Profile 125
COR-005 - Drug Profile 126
cyclosporine - Drug Profile 129
Cyndacel-M - Drug Profile 130
DMX-400 - Drug Profile 131
Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile 132
DT-23552 - Drug Profile 133
DYN-12 - Drug Profile 134
E-1086 - Drug Profile 135
EG-Mirotin - Drug Profile 136
emixustat hydrochloride - Drug Profile 137
FP-008 - Drug Profile 141
GLY-230 - Drug Profile 142
IB-09A0133 - Drug Profile 143
IVMED-60 - Drug Profile 144
JP-153 - Drug Profile 145
KSI-301 - Drug Profile 146
L-779976 - Drug Profile 147
LCB-030110 - Drug Profile 148
Monoclonal Antibody to Inhibit IAP for Diabetic Retinopathy - Drug Profile 149
Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar - Drug Profile 150
MS-553 - Drug Profile 151
MultiGeneEye - Drug Profile 152
Nextomabs - Drug Profile 153
NM-108 - Drug Profile 154
OC-10X - Drug Profile 155
OC-410 - Drug Profile 156
ocriplasmin - Drug Profile 157
OCU-200 - Drug Profile 163
OCX-063 - Drug Profile 164
OLX-302 - Drug Profile 165
PAN-90806 - Drug Profile 166
PF-07 - Drug Profile 168
PRM-167 - Drug Profile 169
Protein for Oncology, Ophthalmology and Metabolic Disorders - Drug Profile 170
ranibizumab biosimilar - Drug Profile 171
ranibizumab biosimilar - Drug Profile 172
ranibizumab biosimilar - Drug Profile 174
RBM-008 - Drug Profile 175
Recombinant Protein for Oncology and Diabetic Retinopathy - Drug Profile 176
Recombinant Protein To Target Caspases for Diabetic Retinopathy, Macular Degeneration and Solid Tumor - Drug Profile 177
RES-529 - Drug Profile 178
ripasudil - Drug Profile 182
RT-001 - Drug Profile 184
RT-002 - Drug Profile 186
RTU-1096 - Drug Profile 187
somatostatin - Drug Profile 188
squalamine lactate - Drug Profile 189
Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 197
Stem Cell Therapy for Diabetic Retinopathy - Drug Profile 203
STNM-1510 - Drug Profile 204
Synthetic Peptide to Agonize PEDF-R for Diabetic Retinopathy - Drug Profile 205
THR-687 - Drug Profile 206
TZ-101 - Drug Profile 207
V-1932 - Drug Profile 210
Wnt-001 - Drug Profile 211
Diabetic Retinopathy - Dormant Projects 212
Diabetic Retinopathy - Discontinued Products 218
Diabetic Retinopathy - Product Development Milestones 219
Featured News & Press Releases 219
Appendix 231
Methodology 231
Coverage 231
Secondary Research 231
Primary Research 231
Expert Panel Validation 231
Contact Us 231
Disclaimer 232
 

List of Tables

List of Tables
Number of Products under Development for Diabetic Retinopathy, H2 2016 16
Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Number of Products under Development by Companies, H2 2016 (Contd..1) 19
Number of Products under Development by Companies, H2 2016 (Contd..2) 20
Number of Products under Development by Companies, H2 2016 (Contd..3) 21
Number of Products under Investigation by Universities/Institutes, H2 2016 22
Comparative Analysis by Late Stage Development, H2 2016 23
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Development, H2 2016 25
Comparative Analysis by Unknown Stage Development, H2 2016 26
Products under Development by Companies, H2 2016 27
Products under Development by Companies, H2 2016 (Contd..1) 28
Products under Development by Companies, H2 2016 (Contd..2) 29
Products under Development by Companies, H2 2016 (Contd..3) 30
Products under Investigation by Universities/Institutes, H2 2016 31
Diabetic Retinopathy - Pipeline by Acucela Inc., H2 2016 32
Diabetic Retinopathy - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 33
Diabetic Retinopathy - Pipeline by Aerpio Therapeutics, Inc., H2 2016 34
Diabetic Retinopathy - Pipeline by Amakem NV, H2 2016 35
Diabetic Retinopathy - Pipeline by Antisense Therapeutics Limited, H2 2016 36
Diabetic Retinopathy - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 37
Diabetic Retinopathy - Pipeline by BCN Peptides, S.A., H2 2016 38
Diabetic Retinopathy - Pipeline by Biomar Microbial Technologies, H2 2016 39
Diabetic Retinopathy - Pipeline by Charlesson LLC., H2 2016 40
Diabetic Retinopathy - Pipeline by Coherus BioSciences, Inc., H2 2016 41
Diabetic Retinopathy - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 42
Diabetic Retinopathy - Pipeline by Diffusion Pharmaceuticals Inc, H2 2016 43
Diabetic Retinopathy - Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 44
Diabetic Retinopathy - Pipeline by Dynamis Therapeutics, Inc., H2 2016 45
Diabetic Retinopathy - Pipeline by EyeGene Inc, H2 2016 46
Diabetic Retinopathy - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016 47
Diabetic Retinopathy - Pipeline by Formycon AG, H2 2016 48
Diabetic Retinopathy - Pipeline by Icon Bioscience, Inc., H2 2016 49
Diabetic Retinopathy - Pipeline by Islet Sciences, Inc., H2 2016 50
Diabetic Retinopathy - Pipeline by Kodiak Sciences Inc., H2 2016 51
Diabetic Retinopathy - Pipeline by Kowa Company, Ltd., H2 2016 52
Diabetic Retinopathy - Pipeline by LegoChem Biosciences, Inc, H2 2016 53
Diabetic Retinopathy - Pipeline by Lpath, Inc., H2 2016 54
Diabetic Retinopathy - Pipeline by M's Science Corporation, H2 2016 55
Diabetic Retinopathy - Pipeline by Mabion SA, H2 2016 56
Diabetic Retinopathy - Pipeline by MingSight Pharmaceuticals, H2 2016 57
Diabetic Retinopathy - Pipeline by OcuCure Therapeutics, Inc., H2 2016 58
Diabetic Retinopathy - Pipeline by Oculis ehf, H2 2016 59
Diabetic Retinopathy - Pipeline by Ohr Pharmaceutical Inc., H2 2016 60
Diabetic Retinopathy - Pipeline by PanOptica, Inc., H2 2016 61
Diabetic Retinopathy - Pipeline by Profarma, H2 2016 62
Diabetic Retinopathy - Pipeline by Promedior, Inc., H2 2016 63
Diabetic Retinopathy - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 64
Diabetic Retinopathy - Pipeline by Retrotope, Inc, H2 2016 65
Diabetic Retinopathy - Pipeline by Ribomic Inc., H2 2016 66
Diabetic Retinopathy - Pipeline by Stelic Institute & Co., Inc., H2 2016 67
Diabetic Retinopathy - Pipeline by Stemedica Cell Technologies, Inc., H2 2016 68
Diabetic Retinopathy - Pipeline by Strongbridge Biopharma plc , H2 2016 69
Diabetic Retinopathy - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 70
Diabetic Retinopathy - Pipeline by Targazyme, Inc., H2 2016 71
Diabetic Retinopathy - Pipeline by ThromboGenics NV, H2 2016 72
Diabetic Retinopathy - Pipeline by TWi Pharmaceuticals, Inc., H2 2016 73
Diabetic Retinopathy - Pipeline by VESSL Therapeutics Ltd, H2 2016 74
Assessment by Monotherapy Products, H2 2016 75
Assessment by Combination Products, H2 2016 76
Number of Products by Stage and Target, H2 2016 78
Number of Products by Stage and Mechanism of Action, H2 2016 82
Number of Products by Stage and Route of Administration, H2 2016 86
Number of Products by Stage and Molecule Type, H2 2016 88
Diabetic Retinopathy - Dormant Projects, H2 2016 217
Diabetic Retinopathy - Dormant Projects (Contd..1), H2 2016 218
Diabetic Retinopathy - Dormant Projects (Contd..2), H2 2016 219
Diabetic Retinopathy - Dormant Projects (Contd..3), H2 2016 220
Diabetic Retinopathy - Dormant Projects (Contd..4), H2 2016 221
Diabetic Retinopathy - Dormant Projects (Contd..5), H2 2016 222
Diabetic Retinopathy - Discontinued Products, H2 2016 223
 

List of Figures

List of Figures
Number of Products under Development for Diabetic Retinopathy, H2 2016 16
Number of Products under Development for Diabetic Retinopathy - Comparative Analysis, H2 2016 17
Number of Products under Development by Companies, H2 2016 18
Comparative Analysis by Clinical Stage Development, H2 2016 24
Comparative Analysis by Early Stage Products, H2 2016 25
Assessment by Monotherapy Products, H2 2016 75
Number of Products by Top 10 Targets, H2 2016 77
Number of Products by Stage and Top 10 Targets, H2 2016 77
Number of Products by Top 10 Mechanism of Actions, H2 2016 81
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 81
Number of Products by Top 10 Routes of Administration, H2 2016 85
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 85
Number of Products by Top 10 Molecule Types, H2 2016 87
Number of Products by Stage and Top 10 Molecule Types, H2 2016 87
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 9, 5, 1, 33, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.Diabetic Retinopathy.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Metabolic Disorders 
Pages: 237 

Companies Featured

Acucela Inc. Aerie Pharmaceuticals, Inc. Aerpio Therapeutics, Inc. Amakem NV Antisense Therapeutics Limited Araim Pharmaceuticals, Inc. BCN Peptides, S.A. Biomar Microbial Technologies Charlesson LLC. Coherus BioSciences, Inc. Crinetics Pharmaceuticals, Inc. Diffusion Pharmaceuticals Inc Dimerix Bioscience Pty Ltd Dynamis Therapeutics, Inc. EyeGene Inc Foresee Pharmaceuticals, LLC Formycon AG Icon Bioscience, Inc. Islet Sciences, Inc. Kodiak Sciences Inc. Kowa Company, Ltd. LegoChem Biosciences, Inc Lpath, Inc. M's Science Corporation Mabion SA MingSight Pharmaceuticals OcuCure Therapeutics, Inc. Oculis ehf Ohr Pharmaceutical Inc. PanOptica, Inc. Profarma Promedior, Inc. Regeneron Pharmaceuticals Inc Retrotope, Inc Ribomic Inc. Stelic Institute & Co., Inc. Stemedica Cell Technologies, Inc. Strongbridge Biopharma plc Sucampo Pharmaceuticals, Inc. Targazyme, Inc. ThromboGenics NV TWi Pharmaceuticals, Inc. VESSL Therapeutics Ltd

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8826IDBPituitary ACTH Hypersecretion (Cushing Disease) - Pipeline Revie...Dec 2016
Report... 05IB-GMDHC8814IDBHyperglycemia - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8807IDBFamilial Amyloid Neuropathies - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8762IDBHeterozygous familial hypercholesterolemia (heFH) - Pipeline Rev...Nov 2016
Report... 05IB-GMDHC8737IDBHomozygous Familial Hypercholesterolemia (HoFH) - Pipeline Revie...Nov 2016
Report... 05IB-GMDHC8697IDBHypercholesterolemia - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8696IDBDiabetic Foot Ulcers - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8653IDBDiabetic Neuropathy - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8770IDBType 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2016Nov 2016

Diabetic Retinopathy - Pipeline Review, H2 2016

Report 05IB-GMDHC8654IDB has a rating of 95 percent
Figure of merit assessment for report 05IB-GMDHC8654IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7184

Taxonomy Location

The taxonomy on the left shows the ancestors of the Metabolic Disorders node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Metabolic Disorders

Metabolic Disorders

 

Healthcare Disorders

Healthcare Disorders

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Diabetic Retinopathy - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8654IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [3.09505s]

--